Recurrence beyond Milan criteria following liver resection for early-stage hepatocellular carcinoma: incidence, prediction and implications for treatment selection.
作者信息
Tsilimigras Diamantis I, Ntanasis-Stathopoulos Ioannis, Moris Dimitrios
机构信息
Division of Surgical Oncology, Department of Surgery, The Ohio State University, Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.
Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
出版信息
Hepatobiliary Surg Nutr. 2025 Apr 1;14(2):305-307. doi: 10.21037/hbsn-2025-45. Epub 2025 Mar 21.
Abstract
摘要
相似文献
1
Recurrence beyond Milan criteria following liver resection for early-stage hepatocellular carcinoma: incidence, prediction and implications for treatment selection.早期肝细胞癌肝切除术后超出米兰标准的复发：发生率、预测及对治疗选择的影响
Hepatobiliary Surg Nutr. 2025 Apr 1;14(2):305-307. doi: 10.21037/hbsn-2025-45. Epub 2025 Mar 21.
2
Non-transplantable Recurrence After Resection for Transplantable Hepatocellular Carcinoma: Implication for Upfront Treatment Choice.可移植性肝细胞癌切除术后不可移植性复发：对初始治疗选择的影响
J Gastrointest Surg. 2022 May;26(5):1021-1029. doi: 10.1007/s11605-021-05206-8. Epub 2021 Nov 19.
3
Overall Tumor Burden Dictates Outcomes for Patients Undergoing Resection of Multinodular Hepatocellular Carcinoma Beyond the Milan Criteria.总体肿瘤负担决定了米兰标准以外的多结节性肝细胞癌患者切除术后的结局。
Ann Surg. 2020 Oct;272(4):574-581. doi: 10.1097/SLA.0000000000004346.
4
Predicting Hepatocellular Carcinoma Recurrence Beyond Milan Criteria After Liver Resection for Solitary Hepatocellular Carcinoma.预测米兰标准以外的单发肝细胞癌肝切除后肝细胞癌复发。
J Gastrointest Surg. 2020 Oct;24(10):2219-2227. doi: 10.1007/s11605-019-04363-1. Epub 2019 Sep 3.
5
α-Fetoprotein model versus Milan criteria in predicting outcomes after hepatic resection for hepatocellular carcinoma: multicentre study.甲胎蛋白模型与米兰标准在预测肝细胞癌肝切除术后结局中的比较：多中心研究
BJS Open. 2025 Mar 4;9(2). doi: 10.1093/bjsopen/zraf041.
6
Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients.射频消融作为潜在可移植患者小于 3cm 的肝细胞癌一线治疗的结果。
J Hepatol. 2019 May;70(5):866-873. doi: 10.1016/j.jhep.2018.12.027. Epub 2019 Jan 5.
7
Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.验证 AFP 模型作为预测病毒肝炎相关性肝硬化患者 HCC 复发的指标，这些患者因 HCC 已接受肝移植。
J Hepatol. 2017 Mar;66(3):552-559. doi: 10.1016/j.jhep.2016.10.038. Epub 2016 Nov 27.
8
Preoperative platelet-to-lymphocyte ratio can predict recurrence beyond the Milan criteria after hepatectomy for patients with hepatocellular carcinoma.术前血小板与淋巴细胞比值可预测肝细胞癌患者肝切除术后超出米兰标准的复发情况。
Hepatol Res. 2017 Sep;47(10):991-999. doi: 10.1111/hepr.12835. Epub 2016 Dec 21.
9
Liver resection versus liver resection plus TACE for patients with hepatocellular carcinoma beyond Milan criteria.对于超出米兰标准的肝细胞癌患者，肝切除术与肝切除术联合经动脉化疗栓塞术的比较
J Surg Res. 2017 Mar;209:8-16. doi: 10.1016/j.jss.2016.09.054. Epub 2016 Oct 4.
10
Liver Resection and Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria.米兰标准以外的肝细胞癌患者的肝切除与肝移植
Ann Surg. 2016 Oct;264(4):650-8. doi: 10.1097/SLA.0000000000001866.
本文引用的文献
1
Histological predictors of aggressive recurrence of hepatocellular carcinoma after liver resection.肝切除术后肝细胞癌侵袭性复发的组织学预测因子。
J Hepatol. 2024 Dec;81(6):995-1004. doi: 10.1016/j.jhep.2024.06.018. Epub 2024 Jun 24.
2
Impact of an artificial intelligence based model to predict non-transplantable recurrence among patients with hepatocellular carcinoma.基于人工智能的模型对肝癌患者非移植性复发的预测影响。
HPB (Oxford). 2024 Aug;26(8):1040-1050. doi: 10.1016/j.hpb.2024.05.006. Epub 2024 May 16.
3
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.阿替利珠单抗联合贝伐珠单抗对比主动监测用于治疗接受手术切除或消融治疗的高风险肝细胞癌患者（IMbrave050）：一项随机、开放标签、多中心、III 期临床试验。
Lancet. 2023 Nov 18;402(10415):1835-1847. doi: 10.1016/S0140-6736(23)01796-8. Epub 2023 Oct 20.
4
Predictors of non-transplantable recurrence in hepatocellular carcinoma patients treated with frontline liver resection.一线肝切除治疗肝细胞癌患者不可移植复发的预测因素。
Liver Int. 2023 Dec;43(12):2762-2775. doi: 10.1111/liv.15719. Epub 2023 Sep 27.
5
TBS-Based Preoperative Score to Predict Non-transplantable Recurrence and Identify Candidates for Upfront Resection Versus Transplantation for Hepatocellular Carcinoma.基于 TBS 的术前评分预测不可移植性复发，并确定肝癌患者行肝切除术与肝移植术的候选者。
Ann Surg Oncol. 2023 Jun;30(6):3363-3373. doi: 10.1245/s10434-023-13273-1. Epub 2023 Feb 23.
6
Risk Factors for Beyond Milan Recurrence After Hepatic Resection for Single Hepatocellular Carcinoma No Larger Than 5 Centimeters.单发直径不超过 5 厘米的肝细胞癌行肝切除术后米兰标准以外复发的危险因素。
Liver Transpl. 2021 Aug;27(8):1116-1129. doi: 10.1002/lt.26070. Epub 2021 Jul 14.
7
Recurrence beyond the Milan criteria after curative-intent resection of hepatocellular carcinoma: A novel tumor-burden based prediction model.米兰标准治疗后肝癌复发：一种基于肿瘤负荷的新预测模型。
J Surg Oncol. 2020 Oct;122(5):955-963. doi: 10.1002/jso.26091. Epub 2020 Jun 29.
8
Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma.肿瘤大小可预测血管侵犯和组织学分级：对肝细胞癌手术治疗选择的意义。
Liver Transpl. 2005 Sep;11(9):1086-92. doi: 10.1002/lt.20472.
Zotero 插件